Zenas BioPharma (ZBIO) Q1 2026 earnings summary

Executive summary

• Report covers the quarter ended March 31, 2026, for a clinical-stage biopharma focused on immunology and inflammation therapies.

• Lead candidate obexelimab showed positive Phase 3 results in IgG4-RD and positive Phase 2 results in relapsing multiple sclerosis.

• Achieved key clinical milestones, including completed enrollment in the Phase 2 SunStone SLE trial and first subject dosed in Phase 1 ZB021 trial.

• Multiple clinical programs are ongoing, including orelabrutinib in MS and early-stage assets ZB021 and ZB022.

• Strengthened balance sheet with $433.5M raised in Q1 2026 and $419M YTD, extending cash runway into 2029.

Financial highlights

• Net loss for Q1 2026 was $81.0 million, up from $33.6 million in Q1 2025.

• Research and development expenses rose to $60.4 million from $34.9 million year-over-year, driven by clinical and regulatory activities.

• General and administrative expenses increased to $16.9 million from $12.4 million, mainly due to higher personnel and pre-commercialization costs.

• No product sales revenue; $10.0 million license revenue recognized in Q1 2025, none in Q1 2026.

• Cash, cash equivalents, and investments totaled $718.5 million as of March 31, 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations into 2029, assuming milestone receipts.

• FDA BLA submission for obexelimab in IgG4-RD expected in Q2 2026; EMA submission in H2 2026.

• Expects topline SLE trial results in Q4 2026 and may initiate Phase 3 in SLE in 2027.

• Initial clinical data from ZB021 Phase 1 expected by year-end 2026.

• Anticipates continued operating losses and negative cash flows as clinical programs advance.